Why did GAAP EPS drop so sharply in the fourth quarter?

GAAP diluted EPS fell to $0.02 from $1.72 mainly because of a $418 million goodwill impairment tied to PharmaLex. The charge is largely not tax-deductible, which pushed the Q4 GAAP effective tax rate to 94.0%. Adjusted EPS, which excludes this item, rose 16.8% to $3.34.

What is driving revenue growth at Cencora?

Growth was driven primarily by U.S. Healthcare Solutions, where revenue rose 15.7% in Q4 on unit volume growth, including higher sales of GLP-1 class diabetes and weight-loss products, and increased specialty product sales to physician practices and health systems. International revenue rose 5.5% in Q4.

What is Cencora's fiscal 2025 outlook?

On an adjusted basis, Cencora expects revenue growth of 7-9%, adjusted operating income growth of 5-6.5%, and adjusted diluted EPS of $14.80-$15.10. Guidance also assumes an adjusted tax rate of about 21%, adjusted free cash flow of $2.0-$3.0 billion, and about 196 million diluted shares. It excludes the pending RCA acquisition, which will be added after closing.

Are the non-GAAP adjustments reasonable for investors to rely on?

Adjusted metrics exclude items such as acquisition-related intangibles amortization, restructuring costs, and litigation and opioid expenses. Some of these recur every year (FY2024 acquisition amortization was $660 million, and litigation and opioid expenses were $227 million), so investors should review GAAP results alongside adjusted figures rather than relying on adjusted measures alone.

What does the dividend increase and leadership change mean for shareholders?

The board raised the quarterly dividend 8% to $0.55 per share, signaling confidence in cash generation. The CEO transition to Robert Mauch was completed October 1, 2024, with Steven Collis moving to Executive Chairman, providing continuity while the company pursues its strategy and the RCA acquisition.

COR 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Cencora (COR) reported fiscal Q4 2024 (quarter ended September 30, 2024) and full-year results that were sharply split between strong underlying operations and a large one-time non-cash charge.

Revenue rose 14.7% to $79.1 billion^a in the quarter and 12.1% to $294.0 billion for the year, driven by U.S. Healthcare Solutions (up 15.7% in the quarter), including strong GLP-1 volume. However, GAAP diluted EPS collapsed to $0.02 from $1.72 a year earlier, primarily due to a $418 million goodwill impairment related to PharmaLex, which is largely non-deductible and pushed the GAAP effective tax rate to 94.0%. On an adjusted basis, quarterly diluted EPS rose 16.8% to $3.34 and full-year adjusted EPS rose 14.8% to $13.76.

Adjusted operating income grew 6.3% in the quarter and 10.9% for the year, though gross margin pressure from lower-margin GLP-1 products was notable. The company also issued fiscal 2025 adjusted guidance calling for 7-9% revenue growth, 5-6.5% adjusted operating income growth, and adjusted diluted EPS of $14.80^b-$15.10 (8-10% growth). Guidance excludes the pending acquisition of Retina Consultants of America, which will be incorporated after closing.

Management also raised the quarterly dividend 8% to $0.55^c per share and completed a CEO transition, with Robert Mauch succeeding Steven Collis (who became Executive Chairman) effective October 1, 2024. Investors should weigh the strong adjusted growth and bullish guidance against the recurring nature of certain 'non-recurring' adjustments (acquisition amortization, restructuring) and the ongoing litigation and opioid-related expenses, which totaled $227 million for the year on a GAAP basis.

02—Key points

Key Highlights

Fiscal Q4 2024 revenue rose 14.7% to $79.1 billion; FY2024 revenue rose 12.1% to $294.0 billion, led by U.S. Healthcare Solutions (+15.7% in Q4).
GAAP diluted EPS fell to $0.02 in Q4 (from $1.72) and $7.53 for FY2024 (down 11.7%), mainly due to a $418M PharmaLex goodwill impairment.
Adjusted diluted EPS grew 16.8% to $3.34 in Q4 and 14.8% to $13.76 for FY2024, showing strong underlying earnings growth.
Gross margin compressed about 12 basis points on a GAAP basis (and 24 basis points adjusted) in Q4, due to lower-margin GLP-1 product sales and the absence of exclusive COVID-19 therapies.
FY2025 adjusted guidance: revenue growth of 7-9%, adjusted operating income growth of 5-6.5%, and adjusted diluted EPS of $14.80-$15.10, excluding the pending RCA acquisition.
Quarterly dividend increased 8% to $0.55 per share (payable November 29, 2024), and about $1.49 billion was spent on share repurchases in FY2024.
CEO transition completed October 1, 2024: Robert Mauch became President and CEO, and Steven Collis became Executive Chairman; the company also announced an agreement to acquire Retina Consultants of America.

03—Questions

Frequently Asked Questions

Why did GAAP EPS drop so sharply in the fourth quarter?
GAAP diluted EPS fell to $0.02 from $1.72 mainly because of a $418 million goodwill impairment tied to PharmaLex. The charge is largely not tax-deductible, which pushed the Q4 GAAP effective tax rate to 94.0%. Adjusted EPS, which excludes this item, rose 16.8% to $3.34.
What is driving revenue growth at Cencora?
Growth was driven primarily by U.S. Healthcare Solutions, where revenue rose 15.7% in Q4 on unit volume growth, including higher sales of GLP-1 class diabetes and weight-loss products, and increased specialty product sales to physician practices and health systems. International revenue rose 5.5% in Q4.
What is Cencora's fiscal 2025 outlook?
On an adjusted basis, Cencora expects revenue growth of 7-9%, adjusted operating income growth of 5-6.5%, and adjusted diluted EPS of $14.80-$15.10. Guidance also assumes an adjusted tax rate of about 21%, adjusted free cash flow of $2.0-$3.0 billion, and about 196 million diluted shares. It excludes the pending RCA acquisition, which will be added after closing.
Are the non-GAAP adjustments reasonable for investors to rely on?
Adjusted metrics exclude items such as acquisition-related intangibles amortization, restructuring costs, and litigation and opioid expenses. Some of these recur every year (FY2024 acquisition amortization was $660 million, and litigation and opioid expenses were $227 million), so investors should review GAAP results alongside adjusted figures rather than relying on adjusted measures alone.
What does the dividend increase and leadership change mean for shareholders?
The board raised the quarterly dividend 8% to $0.55 per share, signaling confidence in cash generation. The CEO transition to Robert Mauch was completed October 1, 2024, with Steven Collis moving to Executive Chairman, providing continuity while the company pursues its strategy and the RCA acquisition.

04—Continue

← View all 8-K filings